WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Boehringer Ingelheim

Boehringer IngelheimThe Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

www.boehringer-ingelheim.com

Boehringer Ingelheim RSS Channel

Filters
List of articles in category Boehringer Ingelheim
Title Published Date
Boehringer Ingelheim will make detailed clinical trial data available to the scientific community 14 May 2014
Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation 06 March 2014
Boehringer Ingelheim receives East Bay Innovation Award 19 February 2014
Crystal Bioscience and Boehringer Ingelheim announce multiple target antibody discovery collaboration 10 February 2014
New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin 04 December 2013
Global Lung Cancer Coalition to identify patient challenges and improve support strategies in partnership with Boehringer Ingelheim 28 October 2013
Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin 07 October 2013
Nintedanib* extended survival beyond one year for advanced adenocarcinoma patients after prior first-line chemotherapy 30 September 2013
Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases 05 September 2013
Benefits of Pradaxa® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure 16 July 2013
Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials 25 June 2013
Boehringer Ingelheim pioneers biopharmaceuticals move to China 06 June 2013
Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, "Complications Combat" 26 May 2013
Boehringer Ingelheim joins Structural Genomics Consortium 08 May 2013
FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate) 26 March 2013
American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education 10 March 2013
New findings from two studies support substantial benefit of Pradaxa® 21 February 2013
FDA grants priority review to Boehringer Ingelheim's Afatinib* NDA for EGFR mutation-positive advanced NSCLC 15 January 2013
Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin 07 January 2013
Boehringer Ingelheim and Apexigen sign manufacturing agreement 06 December 2012
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next
  • End

Business & Industry

  • GSK completes acquisition of Sierra Oncology
  • Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

Research & Development

  • Inhalable COVID-19 vaccine shows promise in rodent model
  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Boehringer Ingelheim
  4. Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.